vTv Therapeutics Inc. Net Income (Loss) Available to Common Stockholders, Diluted
vTv Therapeutics Inc. (VTVT) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$13.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$13.05M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $24.13M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$7.14M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$8.70M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$26.97M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$18.46M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$20.25M.
- vTv Therapeutics Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$19.16M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.05M 10-Q · filed 2026-08-06 | $11.08M 10-Q · filed 2026-08-06 | $3.94M derived: sum of 3 quarters · filed 2026-08-06 | -$4.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.13M 10-Q · filed 2026-05-13 | $17.00M derived: sum of 2 quarters · filed 2026-05-13 | $8.30M derived: sum of 3 quarters · filed 2026-05-13 | $2.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$15.84M derived: sum of 2 quarters · filed 2026-03-10 | -$21.88M derived: sum of 3 quarters · filed 2026-08-06 | -$26.97M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$8.70M 10-Q · filed 2025-11-06 | -$14.74M derived: sum of 2 quarters · filed 2026-08-06 | -$19.84M 10-Q · filed 2025-11-06 | -$23.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$6.05M 10-Q · filed 2026-08-06 | -$11.14M 10-Q · filed 2026-08-06 | -$14.77M derived: sum of 3 quarters · filed 2026-08-06 | -$19.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.09M 10-Q · filed 2026-05-13 | -$8.73M derived: sum of 2 quarters · filed 2026-05-13 | -$13.51M derived: sum of 3 quarters · filed 2026-05-13 | -$18.69M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$8.42M derived: sum of 2 quarters · filed 2026-03-10 | -$13.60M derived: sum of 3 quarters · filed 2026-03-10 | -$18.46M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$4.78M 10-Q · filed 2025-11-06 | -$9.96M derived: sum of 2 quarters · filed 2025-11-06 | -$14.83M 10-Q · filed 2025-11-06 | -$18.31M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-06-30 | -$5.18M 10-Q · filed 2025-08-12 | -$10.04M 10-Q · filed 2025-08-12 | -$13.52M derived: sum of 3 quarters · filed 2026-03-10 | -$20.18M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-03-31 | -$4.87M 10-Q · filed 2025-05-15 | -$8.34M derived: sum of 2 quarters · filed 2026-03-10 | -$15.00M derived: sum of 3 quarters · filed 2026-03-10 | -$20.62M derived: sum of 4 quarters · filed 2026-03-10 |
| 2023-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$10.13M derived: sum of 2 quarters · filed 2026-03-10 | -$15.75M derived: sum of 3 quarters · filed 2026-03-10 | -$20.25M 10-K · filed 2026-03-10 |
| 2023-09-30 | -$6.65M 10-Q · filed 2024-11-12 | -$12.27M derived: sum of 2 quarters · filed 2024-11-12 | -$16.77M 10-Q · filed 2024-11-12 | -$21.52M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | -$5.62M 10-Q · filed 2024-08-08 | -$10.12M 10-Q · filed 2024-08-08 | -$14.86M derived: sum of 3 quarters · filed 2025-03-20 | -$19.12M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | -$4.50M 10-Q · filed 2024-05-09 | -$9.24M derived: sum of 2 quarters · filed 2025-03-20 | -$13.51M derived: sum of 3 quarters · filed 2025-03-20 | -$16.66M derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | -$4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$9.01M derived: sum of 2 quarters · filed 2025-03-20 | -$12.16M derived: sum of 3 quarters · filed 2025-03-20 | -$19.16M 10-K · filed 2025-03-20 |
| 2022-09-30 | -$4.26M 10-Q · filed 2023-11-09 | -$7.41M derived: sum of 2 quarters · filed 2023-11-09 | -$14.42M 10-Q · filed 2023-11-09 | -$21.47M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$3.15M 10-Q · filed 2023-08-11 | -$10.16M 10-Q · filed 2023-08-11 | -$17.21M derived: sum of 3 quarters · filed 2024-03-13 | -$18.30M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$7.01M 10-Q · filed 2023-05-11 | -$14.06M derived: sum of 2 quarters · filed 2024-03-13 | -$15.14M derived: sum of 3 quarters · filed 2024-03-13 | -$15.75M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | -$7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$8.14M derived: sum of 2 quarters · filed 2024-03-13 | -$8.75M derived: sum of 3 quarters · filed 2024-03-13 | -$12.99M 10-K · filed 2024-03-13 |
| 2021-09-30 | -$1.09M 10-Q · filed 2022-11-10 | -$1.70M derived: sum of 2 quarters · filed 2022-11-10 | -$5.94M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$608.00K 10-Q · filed 2022-08-15 | -$4.85M 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | -$8.50M 10-K · filed 2023-03-06 |